Back to top

Image: Bigstock

Are You Looking for a Top Momentum Pick? Why Doctor Reddy's (RDY) is a Great Choice

Read MoreHide Full Article

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Doctor Reddy's (RDY - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Doctor Reddy's currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for RDY that show why this pharmaceutical shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For RDY, shares are up 8.81% over the past week while the Zacks Medical - Generic Drugs industry is up 2.43% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 28.36% compares favorably with the industry's 13.97% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Doctor Reddy's have increased 17.37% over the past quarter, and have gained 25.02% in the last year. On the other hand, the S&P 500 has only moved -13.57% and -1.04%, respectively.

Investors should also pay attention to RDY's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. RDY is currently averaging 256,428 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with RDY.

Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost RDY's consensus estimate, increasing from $1.42 to $1.53 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Given these factors, it shouldn't be surprising that RDY is a #1 (Strong Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Doctor Reddy's on your short list.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Dr. Reddy's Laboratories Ltd (RDY) - free report >>

Published in